Ad5FGF-4
Phase 3Biologic
Ad5FGF-4 is one of 29 biologic programs targeting Myocardial Ischemia. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
40 competitors in Myocardial Ischemia
#DrugCompanyPhaseTrials
1Corlanor
AmgenApproved
Lexapro
AbbVieApproved
Avapro
SanofiApproved
Avelox
BayerApproved
Adenocard
AstellasApproved
Bayer Aspirin
BayerApproved
Plavix
SanofiApproved
Farxiga
AstraZenecaApproved
Accupril
PfizerApproved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ad5FGF-4. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- AAngionetics Inc.